Leadership & Investors
Yair Fisher
Yair is the President of 65Bio and leads all R&D activities. He has extensive experience in drug research and development and held senior positions with biopharmaceutical companies like Bioline, GliXogen Therapeutics and CureTech. Yair received his Ph.D. in Immunology and Neurobiology from the Ben-Gurion University of the Negev.
Jefferson Davis
Jefferson Davis is leading corporate development at 65Bio as well as project management. He is a veteran life science executive with over 25 years’ experience in business and corporate development, research, and project management and financing. Jefferson held senior business and corporate development roles at Genzyme, Archemix, ImmunoGen, GenVec and Eli Lilly. He received a BS in Biochemistry from North Carolina State University and MBA from Duke University.
Daniel Gressel
Daniel is leading all financial aspects of 65Bio supporting also fund raising. He is the president and founder of Teleos Management, LLC, a global macro hedge fund based in Stamford, CT, USA, and a director at the Yankee Institute, a public policy think tank. He previously was a portfolio manager and economist at G.T. Capital Management. He holds a B.S. in Business Administration from Ohio State University, and an M.A. and Ph.D. in economics from the University of Chicago.
Investors
65Bio Inc. is funded by Arkin Holding, a leading pharmaceutical institutional investor as well as by individual pharmaceutical executives.
